)
Visual23 Jan 2026
Waste Management revenue and FCF
Maze Therapeutics
Maze Therapeutics (MAZE) investor relations material
Maze Therapeutics 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary12 Jan, 2026
Strategic vision and pipeline progress
Focus on precision medicines for kidney and metabolic diseases using human genetics, with a strong pipeline and near-term catalysts expected in 2026 and beyond.
Multiple clinical programs underway, including MZE829 for APOL1 kidney disease and MZE782 for PKU and chronic kidney disease.
Operating capital secured into 2028, supporting all planned milestones and studies.
Differentiated platform and team enable execution of milestones and expansion into additional programs.
Commitment to updating stakeholders on progress, with key data readouts expected soon.
MZE829 for APOL1 kidney disease
Addresses a significant unmet need with no approved therapies for APOL1-mediated kidney disease, affecting at least 250,000 individuals in the U.S.
Phase II HORIZON study is ongoing, targeting a clinically meaningful ≥30% reduction in UACR; top-line proof-of-concept data expected by end of Q1 2026.
Study includes both diabetic and non-diabetic patients, with a third cohort for highly proteinuric FSGS patients.
Positive phase I data supported advancement, showing a favorable safety profile and dose selection for broad AMKD.
If successful, planning for phase IIB/III and potential registration strategies will begin.
MZE782 for PKU and chronic kidney disease
MZE782 aims to address PKU by enabling a more normal diet and reducing phenylalanine accumulation, with phase II study initiation planned for mid-2026.
Demonstrated >40-fold increase in urinary phenylalanine excretion in phase I, exceeding benchmarks and generating strong enthusiasm.
Also advancing in chronic kidney disease, with phase II start targeted for the second half of 2026.
Preclinical and phase I data show potential to complement or replace SGLT2 inhibitors, with additive effects and a similar eGFR dip indicating long-term renal protection.
Strategic sequencing prioritizes PKU for a clear registrational path, with pricing and product configuration considerations for broader indications.
MZE829: FSGS cohort data release plan
MZE782: PKU/CKD pricing strategy considerations
MZE782 CKD: SGLT2 complement or replace potential
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Maze Therapeutics earnings date
Q4 20251 Apr, 2026
Maze Therapeutics
Next Maze Therapeutics earnings date
Q4 20251 Apr, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage